Drug intelligence / Profile preview

KAN-NEURO-05

Development stage: Preclinical
Lead developer: Kantify
Modality: Small Molecules

Overview

KAN-NEURO-05 is a preclinical small molecule drug candidate developed by Kantify in collaboration with the University of Antwerp for the treatment of Fragile X Syndrome. Discovered via the Sapian™ AI platform, the compound is designed to modulate multiple novel targets involved in the pathophysiology of the disorder. It is currently in the preclinical stage of development, focusing on hit discovery and lead optimization.

Beyond the preview

Go deeper on KAN-NEURO-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAN-NEURO-05.

Explore the full profile